Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Hold rating and announces Price Target of $120.
Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Hold rating and announces Price Target of $120.